Modular Synthetic Receptor Ligand Binding and Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for transplantation, oncology, and autoimmune disorders lack effective mechanisms for specifically targeting and modulating cellular activities, particularly in recognizing and responding to specific ligands and inducing desired intracellular and extracellular functions.
Innovation Solution
Development of synthetic receptors comprising an extracellular domain for ligand binding, a transmembrane domain derived from Notch receptors, and an intracellular domain that can initiate functional activities upon cleavage, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and secretion of cytokines or chemokines, to modulate target cell activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional therapies are used for transplantation, oncology, and autoimmune disorders, then general treatment is provided, but specific targeting and modulation of cellular activities is insufficient
Solution Approach 1:
The synthetic receptor is divided into three functional domains: an extracellular domain for ligand binding, a transmembrane domain derived from Notch receptors, and an intracellular domain for initiating functional activities. This segmentation allows each domain to be optimized for its specific function while working together to achieve precise target recognition and modulation.
Solution Approach 2:
The synthetic receptor design enables multiple functions through a single construct: it can bind to specific ligands, undergo proteolytic cleavage, release functional domains, and induce both intracellular and extracellular activities. This multi-functionality addresses the need for both specific targeting and versatile therapeutic effects.
2Reliability
If synthetic receptors with multiple domains are created, then specific ligand binding and functional induction are achieved, but structural and functional complexity increases
Solution Approach 1:
The patent combines the extracellular domain, transmembrane domain, and intracellular domain into a single synthetic receptor construct. This merging integrates multiple functions (ligand binding, signal transduction, and functional induction) into one unified structure that operates as a coordinated system, improving reliability while managing complexity through functional integration.
Solution Approach 2:
The transmembrane domain acts as an intermediary between the extracellular ligand-binding domain and the intracellular functional domain. It facilitates signal transduction and enables proteolytic cleavage, serving as a crucial mediator that connects the external ligand recognition with internal functional responses without requiring separate independent components.
3Productivity
If proteolytic cleavage is utilized to release domains, then functional activities are induced, but control over timing and location of release is reduced
Solution Approach 1:
The synthetic receptor employs dynamic proteolytic cleavage to transition from an inactive bound state to an active released state. The cleavage event is triggered by ligand binding and occurs at specific locations within the transmembrane domain, enabling controlled activation of functional domains at the appropriate time and place through dynamic structural changes.
Solution Approach 2:
The extracellular domain binds to the ligand first, establishing the initial complex before proteolytic cleavage occurs. This preliminary binding action positions the molecule correctly and triggers the subsequent cleavage event, ensuring that functional domains are released only after proper ligand engagement and at the correct spatial location.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthetic receptors effectively induce specific cellular responses, such as gene expression, protein-protein interaction blockade, and cytokine secretion, providing a targeted therapeutic approach for cancer, autoimmune disorders, and transplantation by releasing functional domains that can bind to cognate ligands and induce desired activities.
Implementation Method 1
The ability to undergo proteolytic cleavage is contained within a limited region of the Notch receptor, which contains the transmembrane domain and recognition sites for the cleavage event
Data Source
AI summary
Modular synthetic receptors are provided. The synthetic receptors may include an extracellular domain capable of binding to one or more ligand molecules and may be released from the synthetic receptor after binding, a transmembrane domain derived from the Notch receptor, and an intracellular domain which may have one or more functional activities when released from the synthetic receptor. A method of use for the synthetic receptors is also provided, wherein upon binding of the extracellular domain to a specific ligand, the synthetic receptor undergoes proteolytic cleavage to release either or both the extracellular and intracellular domains. The extracellular binding domain, if released, may continue to bind to its cognate ligand and may carry one or more additional functional activities and the intracellular domain, if released, may stimulate or inhibit one or more intracellular activities.